Horien Biotech was listed on the OTC market on July 16th, with its stock price surging over 13% in early trading, showing a honeymoon-like performance. Aiming for a leading position in the global biomedical industry, Haichang's three collagen-based medical devices received the highest-level (TFDA) medical device marketing authorization in Thailand this July. Simultaneously, the company continues to deepen its research and development in medical-grade biomedical raw materials and advanced innovative medical devices, further expanding its global market penetration.
